DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
ChatGPT - 1 Ken Mahoney - 1 Mahoney - 1 Jan Szilagyi - 1 aren't shying - 1 Sylvia Jablonski - 1 Paul Meeks - 1 Meeks - 1
Top related locs:
Hong Kong U.S China
Top related orgs:
Microsoft - 1 Nasdaq - 1 Nvidia - 1 Meta - 1 Apple - 1 Mahoney Asset Management - 1 Nvidia Nvidia - 1 Nvidia — - 1

Search resuls for: "Insilico"


3 mentions found


☆ A.I. enthusiasm drove up stocks this year. Here's how investors can catch the next opportunity
  + stars: | 2023-07-02 | by ( Samantha Subin | ) www.cnbc.com   time to read: +6 min
Six months later, the promise of generative AI has boosted the Nasdaq Composite 31.7%, notching its best first half since 1983 . Betting on Nvidia Nvidia took Wall Street by storm this year. No matter how AI evolves, Nvidia was seen by many investors as a main beneficiary. Even with the stock's stellar performance, and recent entrance into the $1 trillion market cap club, investors aren't shying away just yet. "There will be an opportunity to get into some of these stocks at probably better levels than you're at now," Szilagyi said.
Persons: ChatGPT, Ken Mahoney, Mahoney, Jan Szilagyi, aren't shying, Sylvia Jablonski, Paul Meeks, Meeks, it's, Jordan Stuart, Eli Lilly's Mounjaro, Stuart, Szilagyi Organizations: Microsoft, Nasdaq, Nvidia, Meta, Apple, Mahoney Asset Management, Nvidia Nvidia, Nvidia —, Independent Solutions, Management, Investors, Big Tech, Federated Hermes, Novo Nordisk's Ozempic Locations: Hong Kong
☆ The first fully A.I.-generated drug enters clinical trials in human patients
  + stars: | 2023-06-29 | by ( Hayden Field | ) www.cnbc.com   time to read: +3 min
The first drug fully generated by artificial intelligence entered clinical trials with human patients this week. "It is the first fully generative AI drug to reach human clinical trials, and specifically Phase II trials with patients," Alex Zhavoronkov, founder and CEO of Insilico Medicine, told CNBC. "While there are other AI-designed drugs in trials, ours is the first drug with both a novel AI-discovered target and a novel AI-generated design." One is a Covid-19 drug in phase one clinical trials, and the other is a cancer drug, specifically a "USP1 inhibitor for the treatment of solid tumors," that recently received FDA approval to initiate clinical trials. "I never imagined in those early days that I would be taking my own AI drugs into clinical trials with patients.
Persons: Alex Zhavoronkov, Zhavoronkov, Insilico Organizations: Insilico, National Institutes of Health, CNBC Locations: Hong Kong, U.S, China
☆ How an AI breakthrough from Alphabet's DeepMind 'changed scientific history' and could lead to new cures
  + stars: | 2023-02-28 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +11 min
"AlphaFold has sparked a wave of innovation by showing people what's possible," said Chris Bahl, the chief scientist at AI Proteins, a Boston startup using AlphaFold to help develop drugs. "AlphaFold, amazing as it, is just the beginning," Demis Hassabis, the CEO of DeepMind, said on a podcast last year. AlphaFold2 was built with far more biological and physics knowledge of proteins, Jumper said. Next uses will be 'progressively harder' as DeepMind stays secretive on its future workJohn Jumper, a senior staff research scientist at DeepMind who helped develop AlphaFold. "But AI will also continue to progress rapidly, and the folks at DeepMind are very good, so I'm optimistic."
0 next >>
Total: 3